Tufts Medicine CEO Mike Dandorph is stepping down amid four years of operating losses and upcoming Medicaid reimbursement cuts, according to internal communications obtained by the Boston Globe. Phil Okala, the system’s chief operating officer, will take over as acting president and chief executive officer.
Tufts Medicine Leadership Shakeup and Financial Pressures
The leadership transition arrives as Tufts Medicine deals with persistent financial headwinds that have strained the Boston-area health system. Fiscal year 2025 marked the fourth year in a row the organization operated in the red, according to system records. In the first half of the current fiscal year, Tufts Medicine reported a $46 million loss on operations, a figure some specialists view as a sign of stability, as that loss was similar to its results from the year prior, according to system data.
Outgoing CEO Mike Dandorph called his tenure a “distinct privilege” in a statement released Wednesday. Board chair Richard Lembo credited Dandorph in an internal email with expanding system partnerships and patient access despite “unprecedented financial challenges,” according to the Globe. Alongside Dandorph’s departure, executive vice president and chief financial officer Andrew DeVoe is also leaving the organization, prompting a planned national search for a replacement.
Medicaid Cuts and Payer Mix Challenges
Tufts Medicine faces heavy financial strain from a high proportion of patients insured by government programs, which typically offer lower reimbursement rates than commercial insurers. Data from the Massachusetts Center for Health Information and Analysis shows that approximately two-thirds of patients at three Tufts hospitals—Tufts Medical Center, Lowell General Hospital, and MelroseWakefield Hospital—relied on Medicare or Medicaid in 2024. Impending cuts to Medicaid threaten to deepen these financial pressures, compounding the difficulties of competing against other major Boston-area health networks.
Phil Okala Steps In as Acting CEO
The Tufts Medicine board appointed Chief Operating Officer Phil Okala to serve as acting president and CEO following Dandorph’s departure. Okala brings leadership experience from several major health systems nationwide, including City of Hope in California and Penn Medicine in Pennsylvania, according to internal emails. “Our focus remains unchanged: serving our patients and communities, supporting our people, strengthening our financial position and continuing to advance Tufts Medicine’s mission to empower people to live their best lives,” Okala said in a statement.
Did you know? Approximately two-thirds of patients at Tufts Medical Center, Lowell General Hospital, and MelroseWakefield Hospital were enrolled in Medicare or Medicaid in 2024, according to Massachusetts Center for Health Information and Analysis data.
Frequently Asked Questions
Who is replacing Mike Dandorph at Tufts Medicine?
Phil Okala, the system’s chief operating officer, has been appointed as acting president and CEO by the Tufts Medicine board.
What financial challenges is Tufts Medicine facing?
The health system has operated in the red for four years in a row, including a $46 million operating loss in the first half of the fiscal year, driven partly by high proportions of lower-reimbursing government-insured patients and impending Medicaid cuts.
Is anyone else leaving leadership alongside the CEO?
Yes, executive vice president and chief financial officer Andrew DeVoe is also leaving Tufts Medicine, and the system plans to conduct a national search for his replacement.
Stay informed on New England healthcare news. Explore our latest reporting or subscribe to our newsletter for updates on hospital leadership and regional health economics.
Keep reading